- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilar Articles for the Week of February 15
Here are the top 5 biosimilar articles for the week of February 15, 2021.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilar articles for the week of February 15, 2021.
Number 5: Lannett and HEC Pharm are developing an insulin aspart biosimilar on the heels of their insulin glargine codevelopment project.
Number 4: Biosimilars, supply chain adjustments, building trust, and international standardization were discussed during an international panel of government and industry experts as means to deliver innovation when it's needed, not after.
Number 3: Patients’ demographics and physiological characteristics influence whether they will accept a switch from an originator drug to a biosimilar, according to findings from a New Zealand study.
Number 2: Sandoz Canada said it has launched an adalimumab injectable biosimilar, which is indicated for 9 of the 12 conditions of the originator product (Humira).
Number 1: Celltrion Healthcare has gained EU marketing authorization for the first high-concentration, citrate-free adalimumab biosimilar.
To read all of these articles and more, visit centerforbiosimilars.com.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilars in Action: Market Shifts, Legal Insights, and FDA Approvals
February 9th 2025In this episode of Not So Different, host Skylar Jeremias covers the latest biosimilar developments, including new FDA approvals, patent disputes, and biosimilar market trends shaping the health care landscape.
